12月22日 - Atea Pharmaceuticals Inc :*Atea Pharmaceuticals完成了北美第三阶段试验的患者招募,该试验评估了Bemnifosbuvir和Ruzasvir联合治疗肝炎C病毒的方案*。Atea Pharmaceuticals Inc - C-Beyond项目的初步结果预计于2026年中期公布*。Atea Pharmaceuticals Inc - C-Forward第三阶段试验的初步结果预计在2026年年底发布。
12月22日 - Atea Pharmaceuticals Inc :*Atea Pharmaceuticals完成了北美第三阶段试验的患者招募,该试验评估了Bemnifosbuvir和Ruzasvir联合治疗肝炎C病毒的方案*。Atea Pharmaceuticals Inc - C-Beyond项目的初步结果预计于2026年中期公布*。Atea Pharmaceuticals Inc - C-Forward第三阶段试验的初步结果预计在2026年年底发布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.